Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 3502

Sort by

Sort Order Select

Journal Articles

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Jong Bok Lee, Dilshad H. Khan, Rose Hurren, Mingjing Xu, Yoosu Na, Hyeonjeong Kang, Sara Mirali, Xiaoming Wang, Marcela Gronda, Yulia Jitkova, Neil MacLean, Andrea Arruda, Zoe Alaniz, Marina Y. Konopleva, Michael Andreeff, Mark D. Minden, Li Zhang, Aaron D. Schimmer

Blood (2021) 138 (3): 234–245.

https://doi.org/10.1182/blood.2020009081

Published: 2021

Includes: Supplemental data

Journal Articles

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL

Hanna Kirchhoff, Uemran Karsli, Caroline Schoenherr, Karin Battmer, Sergej Erschow, Steven R. Talbot, Doris Steinemann, Michael Heuser, Olaf Heidenreich, Denise Hilfiker-Kleiner, Arnold Ganser, Matthias Eder, Michaela Scherr

Blood (2021) 137 (19): 2657–2661.

https://doi.org/10.1182/blood.2020008544

Published: 2021

Includes: Supplemental data

Journal Articles

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

Fraser Soares, Branson Chen, Jong Bok Lee, Musaddeque Ahmed, Dalam Ly, Enoch Tin, Hyeonjeong Kang, Yong Zeng, Nayeema Akhtar, Mark D. Minden, Housheng Hansen He, Li Zhang

Blood (2021) 137 (16): 2171–2181.

https://doi.org/10.1182/blood.2019004108

Published: 2021

Includes: Supplemental data

Journal Articles

RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis

Blood (2021) 137 (15): 2033–2045.

https://doi.org/10.1182/blood.2020008738

Published: 2021

Includes: Supplemental data

Journal Articles

Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect

Julien Carvelli, Christelle Piperoglou, Catherine Farnarier, Frédéric Vely, Karin Mazodier, Sandra Audonnet, Patrick Nitschke, Christine Bole-Feysot, Mohamed Boucekine, Audrey Cambon, Mohamed Hamidou, Jean-Robert Harle, Geneviève de Saint Basile, Gilles Kaplanski

Blood (2020) 136 (5): 542–552.

https://doi.org/10.1182/blood.2019003664

Published: 2020

Includes: Supplemental data

Journal Articles

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

Kodandaram Pillarisetti, Suzanne Edavettal, Mark Mendonça, Yingzhe Li, Mark Tornetta, Alexander Babich, Nate Majewski, Matt Husovsky, Dara Reeves, Eileen Walsh, Diana Chin, Leopoldo Luistro, Jocelin Joseph, Gerald Chu, Kathryn Packman, Shoba Shetty, Yusri Elsayed, Ricardo Attar, François Gaudet

Blood (2020) 135 (15): 1232–1243.

https://doi.org/10.1182/blood.2019003342

Published: 2020

Includes: Supplemental data

Journal Articles

High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity

Tom Erkers, Bryan J. Xie, Laura J. Kenyon, Brian Smith, Mary Rieck, Kent P. Jensen, Xuhuai Ji, Marina Basina, Samuel Strober, Robert S. Negrin, Holden T. Maecker, Everett H. Meyer

Blood (2020) 135 (11): 814–825.

https://doi.org/10.1182/blood.2019001903

Published: 2020

Includes: Supplemental data

Journal Articles

A research-driven approach to the identification of novel natural killer cell deficiencies affecting cytotoxic function

Michael T. Lam, Emily M. Mace, Jordan S. Orange

Blood (2020) 135 (9): 629–637.

https://doi.org/10.1182/blood.2019000925

Published: 2020

Journal Articles

Supercharging your CAR

Sneha Ramakrishna, Kara L. Davis

Blood (2020) 135 (9): 593–594.

https://doi.org/10.1182/blood.2019004469

Published: 2020

Journal Articles

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Olli Dufva, Jan Koski, Pilvi Maliniemi, Aleksandr Ianevski, Jay Klievink, Judith Leitner, Petri Pölönen, Helena Hohtari, Khalid Saeed, Tiina Hannunen, Pekka Ellonen, Peter Steinberger, Matti Kankainen, Tero Aittokallio, Mikko A. I. Keränen, Matti Korhonen, Satu Mustjoki

Blood (2020) 135 (9): 597–609.

https://doi.org/10.1182/blood.2019002121

Published: 2020

Includes: Supplemental data

Journal Articles

Carbon Dots As a Potential Therapeutic Agent for Anemia Treatment in Malignancies

Yuanlin Xu, Boyang Wang, Huan Zhang, Xiaoli Qu, Mingming Zhang, Xiuli An, Siyu Lu, Shijie Zhang

Blood (2019) 134 (Supplement_1): 941.

https://doi.org/10.1182/blood-2019-130971

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 1279.

https://doi.org/10.1182/blood-2019-130579

Published: 2019

Journal Articles

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood (2019) 134 (Supplement_1): 762.

https://doi.org/10.1182/blood-2019-122451

Published: 2019

Journal Articles

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

Partow Kebriaei, MD, Pinaki P Banerjee, PhD, Christina Ganesh, BSN, RN, Mecit Kaplan, MS, Vandana Nandivada, BS, MS, Ana Karen Nunez Cortes, MD, Amin M. Alousi, MD, David Marin, MD, Elizabeth J. Shpall, MD, Rohtesh Mehta, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Katayoun Rezvani, MD PhD

Blood (2019) 134 (Supplement_1): 1298.

https://doi.org/10.1182/blood-2019-125931

Published: 2019

Journal Articles

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Srividya Swaminathan, PhD, Line Dam Heftdal, MD, Daniel Liefwalker, PhD, Renumathy Dhanasekaran, MD, Anja Deutzmann, PhD, Crista Horton, BS, Adriane Mosley, BS, Mariola Liebersbach, BS, Andrew Gentles, PhD, Holden T. Maecker, PhD, Dean Felsher, MD PhD

Blood (2019) 134 (Supplement_1): 730.

https://doi.org/10.1182/blood-2019-122607

Published: 2019

Journal Articles

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Fernanda S Seguro, MD, Felipe VR Maciel, MD, Guilherme O Lopes, Luciana Nardinelli, M.Sc, Vanderson Rocha, MD PhD, Israel Bendit, MD PhD

Blood (2019) 134 (Supplement_1): 1651.

https://doi.org/10.1182/blood-2019-125989

Published: 2019

Journal Articles

Targeting Nicotinamide Adenine Dinucleotide (NAD) Glycohydrase Activity of CD38 Exerts Anti-Myeloma Effect Accompanying Intracellular NAD Elevation

Saki Kushima, Takayuki Sasano, Masao Matsuoka, MD PhD, Hiroyuki Hata, MD PhD, Yawara Kawano, MD PhD

Blood (2019) 134 (Supplement_1): 1810.

https://doi.org/10.1182/blood-2019-123624

Published: 2019

Journal Articles

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Takayuki Sasano, Saki Kushima, Matsushita Yutaka, Masao Matsuoka, MD PhD, Hiroyuki Hata, MD PhD, Yawara Kawano, MD PhD

Blood (2019) 134 (Supplement_1): 1814.

https://doi.org/10.1182/blood-2019-123619

Published: 2019

Journal Articles

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Lijie Xing, MD, Liang Lin, PhD, Tengteng Yu, MD PhD, Yuyin Li, PhD, Kenneth Wen, BS, Shih-Feng Cho, MD PhD, Phillip A Hsieh, Krista Kinneer, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Yu-Tzu Tai, PhD

Blood (2019) 134 (Supplement_1): 1817.

https://doi.org/10.1182/blood-2019-127163

Published: 2019

NARROW

Venetoclax enhances T cell–mediated antileukemic activity by increasing ROS production

Venetoclax and dexamethasone synergize with inotuzumab ozogamicin–induced DNA damage signaling in B-lineage ALL

CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy

RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis

Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect

A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma

High-parametric evaluation of human invariant natural killer T cells to delineate heterogeneity in allo- and autoimmunity

A research-driven approach to the identification of novel natural killer cell deficiencies affecting cytotoxic function

Supercharging your CAR

Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity

Carbon Dots As a Potential Therapeutic Agent for Anemia Treatment in Malignancies

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blinatumomab Is Well Tolerated Maintenance Therapy Following Allogeneic Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial

Targeting Nicotinamide Adenine Dinucleotide (NAD) Glycohydrase Activity of CD38 Exerts Anti-Myeloma Effect Accompanying Intracellular NAD Elevation

JX06, a Novel PDK1 Inhibitor, Induces Myeloma Cell Apoptosis By Metabolic Reprogramming and Works Synergistically with Bortezomib

Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only